Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 934

1.

Exome Sequencing in BRCA1- and BRCA2-Negative Greek Families Identifies MDM1 and NBEAL1 as Candidate Risk Genes for Hereditary Breast Cancer.

Glentis S, Dimopoulos AC, Rouskas K, Ntritsos G, Evangelou E, Narod SA, Mes-Masson AM, Foulkes WD, Rivera B, Tonin PN, Ragoussis J, Dimas AS.

Front Genet. 2019 Oct 18;10:1005. doi: 10.3389/fgene.2019.01005. eCollection 2019.

2.

Effect of a Knowledge-Translation Intervention on Breast Surgeons' Oncofertility Attitudes and Practices.

Warner E, Yee S, Seminsky M, Glass K, Foong S, Kennedy E, Narod S, Quan ML.

Ann Surg Oncol. 2019 Oct 28. doi: 10.1245/s10434-019-07972-x. [Epub ahead of print]

PMID:
31659644
3.

Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?

Kotsopoulos J, Gronwald J, Lubinski J, McCuaig J, Lynch HT, Neuhausen SL, Foulkes WD, Weitzel JN, Senter L, Tung N, Eng C, Karlan B, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Menopause. 2019 Oct 21. doi: 10.1097/GME.0000000000001437. [Epub ahead of print]

PMID:
31644510
4.

Inherited Variants in BLM and the Risk and Clinical Characteristics of Breast Cancer.

Kluźniak W, Wokołorczyk D, Rusak B, Huzarski T, Kashyap A, Stempa K, Rudnicka H, Jakubowska A, Szwiec M, Morawska S, Gliniewicz K, Mordak K, Stawicka M, Jarkiewicz-Tretyn J, Cechowska M, Domagała P, Dębniak T, Lener M, Gronwald J, Lubiński J, Narod SA, Akbari MR, Cybulski C.

Cancers (Basel). 2019 Oct 13;11(10). pii: E1548. doi: 10.3390/cancers11101548.

5.

A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy.

Gronwald J, Lubinski J, Huzarski T, Cybulski C, Menkiszak J, Siołek M, Stawicka M, Sun P, Kim SJ, Kotsopoulos J, Narod SA.

Gynecol Oncol. 2019 Nov;155(2):270-274. doi: 10.1016/j.ygyno.2019.08.034. Epub 2019 Sep 26.

PMID:
31500890
6.

MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc).

Narod SA.

Lancet Oncol. 2019 Sep;20(9):e465. doi: 10.1016/S1470-2045(19)30489-9. No abstract available.

PMID:
31486364
7.

BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer.

Prajzendanc K, Domagała P, Hybiak J, Ryś J, Huzarski T, Szwiec M, Tomiczek-Szwiec J, Redelbach W, Sejda A, Gronwald J, Kluz T, Wiśniowski R, Cybulski C, Łukomska A, Białkowska K, Sukiennicki G, Kulczycka K, Narod SA, Wojdacz TK, Lubiński J, Jakubowska A.

Int J Cancer. 2019 Aug 30. doi: 10.1002/ijc.32655. [Epub ahead of print]

PMID:
31469414
8.

Inherited variants in XRCC2 and the risk of breast cancer.

Kluźniak W, Wokołorczyk D, Rusak B, Huzarski T, Gronwald J, Stempa K, Rudnicka H, Kashyap A, Dębniak T, Jakubowska A, Lener M, Szwiec M, Tomiczek-Szwiec J, Jarkiewicz-Tretyn J, Cechowska M, Domagała P, Szymiczek A, Bagherzadeh M, Lubiński J, Narod SA, Akbari MR, Cybulski C; Polish Hereditary Breast Cancer Consortium.

Breast Cancer Res Treat. 2019 Dec;178(3):657-663. doi: 10.1007/s10549-019-05415-5. Epub 2019 Aug 28.

9.

Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.

Cerretini R, Mercado G, Morganstein J, Schiaffi J, Reynoso M, Montoya D, Valdéz R, Narod SA, Akbari MR.

Breast Cancer Res Treat. 2019 Dec;178(3):629-636. doi: 10.1007/s10549-019-05411-9. Epub 2019 Aug 24.

PMID:
31446535
10.

Allelic modification of breast cancer risk in women with an NBN mutation.

Rusak B, Kluźniak W, Wokołorczyk D, Stempa K, Kashyap A, Rudnicka H, Gronwald J, Huzarski T, Dębniak T, Jakubowska A, Szwiec M, Akbari MR, Narod SA, Lubiński J, Cybulski C; Polish Hereditary Breast Cancer Consortium.

Breast Cancer Res Treat. 2019 Nov;178(2):427-431. doi: 10.1007/s10549-019-05391-w. Epub 2019 Aug 13.

PMID:
31410679
11.

Changes in Bone Mineral Density After Prophylactic Bilateral Salpingo-Oophorectomy in Carriers of a BRCA Mutation.

Kotsopoulos J, Hall E, Finch A, Hu H, Murphy J, Rosen B, Narod SA, Cheung AM.

JAMA Netw Open. 2019 Aug 2;2(8):e198420. doi: 10.1001/jamanetworkopen.2019.8420.

12.

Blood arsenic levels and the risk of familial breast cancer in Poland.

Marciniak W, Derkacz R, Muszyńska M, Baszuk P, Gronwald J, Huzarski T, Cybulski C, Jakubowska A, Falco M, Dębniak T, Lener M, Oszurek O, Pullella K, Kotsopoulos J, Sun P, Narod SA, Lubiński J.

Int J Cancer. 2019 Jul 26. doi: 10.1002/ijc.32595. [Epub ahead of print]

PMID:
31348523
13.

Countercurrents: Is now the right time to pull the plug on mammography?

Narod SA.

Curr Oncol. 2019 Jun;26(3):162-163. doi: 10.3747/co.26.4835. Epub 2019 Jun 1. No abstract available.

14.

A generalizable relationship between mortality and time-to-death among breast cancer patients can be explained by tumour dormancy.

Giannakeas V, Narod SA.

Breast Cancer Res Treat. 2019 Oct;177(3):691-703. doi: 10.1007/s10549-019-05334-5. Epub 2019 Jul 1.

15.

Predictors of mammographic density among women with a strong family history of breast cancer.

Moran O, Eisen A, Demsky R, Blackmore K, Knight JA, Panchal S, Ginsburg O, Zbuk K, Yaffe M, Metcalfe KA, Narod SA, Kotsopoulos J.

BMC Cancer. 2019 Jun 26;19(1):631. doi: 10.1186/s12885-019-5855-2.

16.

Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study.

Harris HR, Cushing-Haugen KL, Webb PM, Nagle CM, Jordan SJ; Australian Ovarian Cancer Study Group, Risch HA, Rossing MA, Doherty JA, Goodman MT, Modugno F, Ness RB, Moysich KB, Kjær SK, Høgdall E, Jensen A, Schildkraut JM, Berchuck A, Cramer DW, Bandera EV, Rodriguez L, Wentzensen N, Kotsopoulos J, Narod SA, McLaughlin JR, Anton-Culver H, Ziogas A, Pearce CL, Wu AH, Lindström S, Terry KL.

Int J Epidemiol. 2019 Jun 1;48(3):822-830. doi: 10.1093/ije/dyz113.

PMID:
31211375
17.

Genetic testing for breast cancer in the Hispanic community.

Narod SA.

Cancer. 2019 Aug 15;125(16):2728-2729. doi: 10.1002/cncr.32334. Epub 2019 Jun 17. No abstract available.

PMID:
31206622
18.

The spectrum of mutations predisposing to familial breast cancer in Poland.

Cybulski C, Kluźniak W, Huzarski T, Wokołorczyk D, Kashyap A, Rusak B, Stempa K, Gronwald J, Szymiczek A, Bagherzadeh M, Jakubowska A, Dębniak T, Lener M, Rudnicka H, Szwiec M, Jarkiewicz-Tretyn J, Stawicka M, Domagała P, Narod SA, Lubiński J, Akbari MR; Polish Hereditary Breast Cancer Consortium.

Int J Cancer. 2019 Dec 15;145(12):3311-3320. doi: 10.1002/ijc.32492. Epub 2019 Jun 26.

PMID:
31173646
19.

Is bilateral radiation an option for BRCA mutation carriers with unilateral breast cancer?

Narod SA.

Ann Transl Med. 2019 Apr;7(8):165. doi: 10.21037/atm.2019.03.27. No abstract available.

20.

Gender bias in CIHR Foundation grant awarding.

Giannakeas V, Sopik V, Narod S.

Lancet. 2019 Jun 1;393(10187):2195. doi: 10.1016/S0140-6736(19)31103-1. No abstract available.

PMID:
31162072
21.

BARD1 is A Low/Moderate Breast Cancer Risk Gene: Evidence Based on An Association Study of the Central European p.Q564X Recurrent Mutation.

Suszynska M, Kluzniak W, Wokolorczyk D, Jakubowska A, Huzarski T, Gronwald J, Debniak T, Szwiec M, Ratajska M, Klonowska K, Narod S, Bogdanova N, Dörk T, Lubinski J, Cybulski C, Kozlowski P.

Cancers (Basel). 2019 May 28;11(6). pii: E740. doi: 10.3390/cancers11060740.

22.

Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Zaman T, Sun P, Narod SA, Salmena L, Kotsopoulos J.

Oncotarget. 2019 Mar 29;10(25):2475-2483. doi: 10.18632/oncotarget.26810. eCollection 2019 Mar 29.

23.

International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.

Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS, Pal T, Lynch HT, Tung NM, Kwong A, Ainsworth P, Karlan B, Moller P, Eng C, Weitzel JN, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Br J Cancer. 2019 Jul;121(1):15-21. doi: 10.1038/s41416-019-0446-1. Epub 2019 Apr 11.

PMID:
30971774
24.

Genome-wide Analysis of Common Copy Number Variation and Epithelial Ovarian Cancer Risk.

Reid BM, Permuth JB, Chen YA, Fridley BL, Iversen ES, Chen Z, Jim H, Vierkant RA, Cunningham JM, Barnholtz-Sloan JS, Narod S, Risch H, Schildkraut JM, Goode EL, Monteiro AN, Sellers TA.

Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1117-1126. doi: 10.1158/1055-9965.EPI-18-0833. Epub 2019 Apr 4.

PMID:
30948450
25.

CHEK2 Alleles Predispose to Renal Cancer in Poland.

Zlowocka-Perlowska E, Narod SA, Cybulski C.

JAMA Oncol. 2019 Apr 1;5(4):576. doi: 10.1001/jamaoncol.2019.0022. No abstract available.

PMID:
30816943
26.

Author response to "a response to 'personalised medicine and population health: breast and ovarian cancer'".

Narod SA.

Hum Genet. 2019 Mar;138(3):291-292. doi: 10.1007/s00439-019-01981-2. Epub 2019 Feb 21.

PMID:
30790050
27.

Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Lubinski J, Lynch HT, Tung N, Armel S, Senter L, Singer CF, Fruscio R, Couch F, Weitzel JN, Karlan B, Foulkes WD, Moller P, Eisen A, Ainsworth P, Neuhausen SL, Olopade O, Sun P, Gronwald J, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Breast Cancer Res Treat. 2019 Jun;175(2):443-449. doi: 10.1007/s10549-019-05162-7. Epub 2019 Feb 12.

PMID:
30756284
28.

The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening.

Giannakeas V, Narod SA.

Cancer. 2019 Jun 15;125(12):2130. doi: 10.1002/cncr.32008. Epub 2019 Feb 12. No abstract available.

PMID:
30748004
29.

Oestrogen receptor status and survival in women with BRCA2-associated breast cancer.

Metcalfe K, Lynch HT, Foulkes WD, Tung N, Olopade OI, Eisen A, Lerner-Ellis J, Snyder C, Kim SJ, Sun P, Narod SA.

Br J Cancer. 2019 Feb;120(4):398-403. doi: 10.1038/s41416-019-0376-y. Epub 2019 Feb 6.

PMID:
30723304
30.

Computer-Assisted Flagging of Individuals at High Risk of Colorectal Cancer in a Large Health Maintenance Organization Using the ColonFlag Test.

Goshen R, Choman E, Ran A, Muller E, Kariv R, Chodick G, Ash N, Narod S, Shalev V.

JCO Clin Cancer Inform. 2018 Dec;2:1-8. doi: 10.1200/CCI.17.00130.

31.

Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy.

Giannakeas V, Sopik V, Narod SA.

JAMA Netw Open. 2018 Aug 3;1(4):e181100. doi: 10.1001/jamanetworkopen.2018.1100. Erratum in: JAMA Netw Open. 2019 Aug 2;2(8):e1911052.

32.

Association Between Invasive Lobular Breast Cancer and Mutations in the Mismatch Repair Gene MSH6.

Narod S.

JAMA Oncol. 2019 Jan 1;5(1):120. doi: 10.1001/jamaoncol.2018.6908. No abstract available.

PMID:
30629137
33.

Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers.

Lubinski J, Huzarski T, Gronwald J, Cybulski C, Debniak T, Sun P, Kim SJ, Kotsopoulos J, Narod SA.

Breast Cancer Res Treat. 2019 Apr;174(3):769-774. doi: 10.1007/s10549-018-05076-w. Epub 2019 Jan 5.

PMID:
30612273
34.

Folic acid supplement use and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a case-control study.

Kim SJ, Zhang CXW, Demsky R, Armel S, Kim YI, Narod SA, Kotsopoulos J.

Breast Cancer Res Treat. 2019 Apr;174(3):741-748. doi: 10.1007/s10549-018-05118-3. Epub 2019 Jan 2.

PMID:
30603998
35.

The cost of treatment and its related complications for men who receive surgery or radiation therapy for prostate cancer.

Garbens A, Wallis CJD, Matta R, Kodama R, Herschorn S, Narod S, Nam RK.

Can Urol Assoc J. 2018 Dec 3:E236-E248. doi: 10.5489/cuaj.5598. [Epub ahead of print]

36.

A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.

Donenberg T, George S, Ali J, Bravo G, Hernandez K, Sookar N, Ashing KT, Narod SA, Akbari MR, Hurley J.

Breast Cancer Res Treat. 2019 Apr;174(2):469-477. doi: 10.1007/s10549-018-5045-y. Epub 2018 Dec 4.

PMID:
30515680
37.

Prediction of findings at screening colonoscopy using a machine learning algorithm based on complete blood counts (ColonFlag).

Hilsden RJ, Heitman SJ, Mizrahi B, Narod SA, Goshen R.

PLoS One. 2018 Nov 27;13(11):e0207848. doi: 10.1371/journal.pone.0207848. eCollection 2018.

38.

Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomy.

Chandrasekar T, Narod SA, Nam RK.

JAMA Oncol. 2018 Nov 1;4(11):1620. doi: 10.1001/jamaoncol.2018.3539. No abstract available.

PMID:
30422247
39.

Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study.

Giannakeas V, Cadarette SM, Ban JK, Lipscombe L, Narod SA, Kotsopoulos J.

Br J Cancer. 2018 Nov;119(11):1421-1427. doi: 10.1038/s41416-018-0225-4. Epub 2018 Nov 13.

40.

Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.

Hall E, Finch A, Jacobson M, Rosen B, Metcalfe K, Sun P, Narod SA, Kotsopoulos J.

Gynecol Oncol. 2019 Jan;152(1):145-150. doi: 10.1016/j.ygyno.2018.10.040. Epub 2018 Nov 7.

PMID:
30414741
41.

Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer.

Narod SA.

JAMA Oncol. 2018 Dec 1;4(12):1787-1788. doi: 10.1001/jamaoncol.2018.4931. No abstract available.

PMID:
30383137
42.

Personalised medicine and population health: breast and ovarian cancer.

Narod SA.

Hum Genet. 2018 Oct;137(10):769-778. doi: 10.1007/s00439-018-1944-6. Epub 2018 Oct 17. Review.

PMID:
30328515
43.

Predictors of time to death after distant recurrence in breast cancer patients.

Sopik V, Sun P, Narod SA.

Breast Cancer Res Treat. 2019 Jan;173(2):465-474. doi: 10.1007/s10549-018-5002-9. Epub 2018 Oct 16.

PMID:
30328050
44.

Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US.

McGrath LJ, Overman RA, Reams D, Cetin K, Liede A, Narod SA, Brookhart MA, Hernandez RK.

Clin Epidemiol. 2018 Sep 26;10:1349-1358. doi: 10.2147/CLEP.S175063. eCollection 2018.

45.

Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.

Visvanathan K, Shaw P, May BJ, Bahadirli-Talbott A, Kaushiva A, Risch H, Narod S, Wang TL, Parkash V, Vang R, Levine DA, Soslow R, Kurman R, Shih IM.

Cancer Prev Res (Phila). 2018 Nov;11(11):697-706. doi: 10.1158/1940-6207.CAPR-18-0009. Epub 2018 Sep 19.

46.

Reply to 'Mutations in RECQL are not associated with breast cancer risk in an Australian population'.

Ahmed H, Lerner-Ellis J, Cybulski C, Metcalfe K, Lubiński J, Narod SA, Akbari MR.

Nat Genet. 2018 Oct;50(10):1348-1349. doi: 10.1038/s41588-018-0233-6. No abstract available.

PMID:
30224648
47.

Time to death in breast cancer patients as an indicator of treatment response.

Narod SA, Giannakeas V, Sopik V.

Breast Cancer Res Treat. 2018 Dec;172(3):659-669. doi: 10.1007/s10549-018-4935-3. Epub 2018 Aug 30.

48.

rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology.

Kelemen LE, Earp M, Fridley BL, Chenevix-Trench G; Australian Ovarian Cancer Study Group, Fasching PA, Beckmann MW, Ekici AB, Hein A, Lambrechts D, Lambrechts S, Van Nieuwenhuysen E, Vergote I, Rossing MA, Doherty JA, Chang-Claude J, Behrens S, Moysich KB, Cannioto R, Lele S, Odunsi K, Goodman MT, Shvetsov YB, Thompson PJ, Wilkens LR, Dörk T, Antonenkova N, Bogdanova N, Hillemanns P, Runnebaum IB, du Bois A, Harter P, Heitz F, Schwaab I, Butzow R, Pelttari LM, Nevanlinna H, Modugno F, Edwards RP, Kelley JL, Ness RB, Karlan BY, Lester J, Orsulic S, Walsh C, Kjaer SK, Jensen A, Cunningham JM, Vierkant RA, Giles GG, Bruinsma F, Southey MC, Hildebrandt MAT, Liang D, Lu K, Wu X, Sellers TA, Levine DA, Schildkraut JM, Iversen ES, Terry KL, Cramer DW, Tworoger SS, Poole EM, Bandera EV, Olson SH, Orlow I, Vestrheim Thomsen LC, Bjorge L, Krakstad C, Tangen IL, Kiemeney LA, Aben KKH, Massuger LFAG, van Altena AM, Pejovic T, Bean Y, Kellar M, Cook LS, Le ND, Brooks-Wilson A, Gronwald J, Cybulski C, Jakubowska A, Lubiński J, Wentzensen N, Brinton LA, Lissowska J, Hogdall E, Engelholm SA, Hogdall C, Lundvall L, Nedergaard L, Pharoah PDP, Dicks E, Song H, Tyrer JP, McNeish I, Siddiqui N, Carty K, Glasspool R, Paul J, Campbell IG, Eccles D, Whittemore AS, McGuire V, Rothstein JH, Sieh W, Narod SA, Phelan CM, McLaughlin JR, Risch HA, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Gentry-Maharaj A, Ramus SJ, Wu AH, Pearce CL, Lee AW, Pike MC, Kupryjanczyk J, Podgorska A, Plisiecka-Halasa J, Sawicki W, Goode EL, Berchuck A; Ovarian Cancer Association Consortium.

Int J Mol Sci. 2018 Aug 21;19(9). pii: E2473. doi: 10.3390/ijms19092473.

49.

Clinical Cancer Genetics in a Lower-Middle Income Country: Considerations for Policymaking.

Ginsburg O, Narod SA.

J Glob Oncol. 2018 Jul;4:1-3. doi: 10.1200/JGO.18.00081. No abstract available.

50.

RE: Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer.

Wallis CJD, Akbari MR, Narod SA, Nam RK.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx105. No abstract available.

PMID:
30053076

Supplemental Content

Support Center